文献速递妇科

贝伐珠单抗联合化疗治疗铂耐药卵巢癌的真实世界结局

Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer.
PubMed 文献 · Gynecol Oncol · 2024-01-28

加拿大安大略省行政数据库分析2017至2019年176例铂耐药卵巢癌接受贝伐珠单抗治疗的患者,中位治疗时间3个月、中位总生存11个月;贝伐珠单抗联合紫杉醇较联合脂质体多柔比星的治疗时间和总生存更长;贝伐珠单抗获批资助前后总生存无显著差异。

要点

  • 真实世界中位治疗时间3个月、中位总生存11个月,劣于关键临床试验。
  • 贝伐珠单抗联合紫杉醇较联合脂质体多柔比星治疗时间(6 vs 3个月)和总生存(14 vs 9个月)更长。
  • 贝伐珠单抗资助前后总生存无显著差异(8 vs 9个月,HR 1.01)。

核心结论

  • 铂耐药卵巢癌贝伐珠单抗真实世界结局劣于关键临床试验,资助后生存未显著改善,提示疗效-效果差距。
  • 贝伐珠单抗联合紫杉醇时中位总生存和治疗时间显著优于联合脂质体多柔比星。

研究设计与样本

  • 利用加拿大安大略省行政数据库识别所有接受贝伐珠单抗治疗的铂耐药卵巢癌患者。
  • 2017至2019年共176例患者接受贝伐珠单抗治疗。
  • 采用Kaplan-Meier法确定中位总生存,Cox比例风险模型识别与治疗时间和总生存相关的因素,并进行贝伐珠单抗批准前后比较效果分析。

主要发现

  • 中位治疗时间3个月,中位总生存11个月。
  • 64%接受脂质体多柔比星,34%接受紫杉醇。
  • 贝伐珠单抗联合紫杉醇较联合脂质体多柔比星的治疗时间更长(6 vs 3个月;HR 0.44;p < 0.0001),总生存更长(14 vs 9个月;HR 0.45;p = 0.0089)。
  • 贝伐珠单抗资助前后总生存无显著差异(8 vs 9个月;HR 1.01;p = 0.937)。
  • 接受紫杉醇者中位总生存增加(6 vs 11个月),但资助后组更年轻、更可能接受初次手术且合并症更少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The addition of bevacizumab to chemotherapy for platinum-resistant (PL-R) ovarian cancer (OC) improved progression-free (PFS) but not overall survival (OS) in clinical trials. We explored real-world outcomes in Ontario, Canada, and compared survival in the pre- and post-bevacizumab era. METHODS: Administrative databases were utilized to identify all patients treated with bevacizumab for PL-R OC. Time on treatment (ToT) was used as surrogate for PFS. Median OS was determined using the Kaplan-Meier method. Factors associated with ToT/OS were identified using a Cox proportional hazard model. A before and after comparative effectiveness analysis was performed to determine mOS for patients treated pre- and post-bevacizumab approval. RESULTS: From 2017 to 2019, 176 patients received bevacizumab. Median ToT was 3 months and OS was 11 months. Sixty-four percent received liposomal doxorubicin and 34% received paclitaxel. ToT (6 vs 3 months; HR 0.44; p < 0.0001) and OS (14 vs 9 months; HR 0.45; p = 0.0089) were longer with bevacizumab/paclitaxel. OS was not significantly different pre- and post-bevacizumab funding (8 vs 9 months; HR 1.01; 0.937). Median OS increased for those receiving paclitaxel (6 vs 11 months), but those in the post group were younger, more likely to have undergone primary surgery and had less co-morbidities. CONCLUSION: Real-world outcomes with bevacizumab in PL-R OC are inferior to those in the pivotal clinical trial. Survival has not significantly improved since funding became publicly available, indicating a substantial efficacy-effectiveness gap between trial and real-world outcomes. Median OS and ToT were significantly better when bevacizumab was given with paclitaxel.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Moffat GT, Kong W, MacKay HJ, et al. Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian Cancer. Gynecol Oncol. 2024. PMID: 38281412. doi:10.1016/j.ygyno.2024.01.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。